beta
/Combination Therapy With Actriib Receptor Variants And Glp-1 Agonists
Abstract

The present disclosure provides combinations of TGFβ superfamily ligand binding agents and GLP-1 agonists, compositions thereof, and methods of use in the treatment of metabolic disorders.

Full Text

What is claimed is:

The present disclosure provides combinations of TGFβ superfamily ligand binding agents and GLP-1 agonists, compositions thereof, and methods of use in the treatment of metabolic disorders.
Timeline
Filed
03/06/2026
Published
07/09/2026
Granted
Not Available
IPC Codes(5)
C07K 14/71:for growth factors; for growth regulators
A61K 9/00:Medicinal preparations characterised by special physical form
A61K 47/64:Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K 47/65)